3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
21
Metastatic Castration-resistant Prostate Cancer
3
Prostatic Neoplasms, Castration-Resistant
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Renal Insufficiency
1
Prostatic Diseases
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Liver Neoplasms
1
Kidney Neoplasms
1
High-Risk Localized Prostate Cancer
1
Glioma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Disease
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Astrocytoma
1
Anemia
1
Interventions
Magnetic Resonance Imaging
2
Cryosurgery
2
imetelstat
1
Waiting Lists
1
Transcutaneous Electric Nerve Stimulation
1
S-Adenosylmethionine
1
Prostatectomy
1
Pluvicto
1
Observation
1
Nivolumab
1
Mammography
1
High-Intensity Interval Training
1
Hematologic Tests
1
Fluorodeoxyglucose F18
1
Exercise
1
Equipment and Supplies
1
Educational Status
1
Diagnostic Techniques and Procedures
1
Diagnosis, Computer-Assisted
1
Bupivacaine
1
Blood Specimen Collection
1
Artificial Intelligence
1
Arginine
1
Acupressure
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
Pluvicto
×
90 days
×
Clear all
NCT07054346
2026-04-01
LUTACT
University of California, San Francisco
Phase 1
Recruiting
45 enrolled